AbbVie

AbbVie Net Margin

The Net Profit Margin of AbbVie (ABBV) as of Nov 10, 2026 is 6.91 %. In the previous year, Net Profit Margin was 7.59 % — a change of -9.01% (lower).

Net Margin

6.91 %

YoY

-9.01%

Last updated:

Net Profit Margin of AbbVie is 2025 6.91 % . Net Profit Margin of AbbVie was 2024 7.59 % . It decreases by -9.01% lower compared to the previous year.

For AbbVie, the net margin of 6.9% is down versus 20.5% a few years ago.

The AbbVie Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
17.36 USD
Jan 1, 2019
23.69 USD
Jan 1, 2020
10.08 USD
Jan 1, 2021
20.54 USD
Jan 1, 2022
20.39 USD
Jan 1, 2023
8.95 USD
Jan 1, 2024
7.59 USD
Jan 1, 2025
6.91 USD
The AbbVie Net Margin history
YEARNet MarginYoY
6.91 %-9.01%
7.59 %-15.18%
8.95 %-56.09%
20.39 %-0.73%
20.54 %+103.80%
10.08 %-57.47%
23.69 %+36.46%
17.36 %-7.72%
18.82 %-18.97%
23.22 %+3.18%
22.50 %+153.19%
8.89 %+3,945.57%
0.22 %-23.45%
0.29 %+45.83%
0.20 %-26.34%
0.27 %-18.09%
0.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AbbVie Stock analysis

What does AbbVie do? Abbvie Inc. is a global, research-oriented company specializing in the field of biotechnology and pharmaceuticals. It was founded in 2013 as a spin-off from Abbott Laboratories. Abbvie's headquarters are in North Chicago, Illinois, and it employs over 47,000 people in more than 75 countries worldwide. The company focuses on researching, developing, and marketing high-quality therapies for the treatment of serious and life-threatening diseases. Abbvie has several business divisions, including immunology, oncology, neurology, and virology, and is known for its investments in research and development. Its key products include adalimumab (sold under the brand name Humira) for autoimmune diseases and Imbruvica for chronic lymphocytic leukemia. Abbvie is recognized as a leading company in the biotechnology and pharmaceutical industry due to its focus on innovative therapies and medicines. AbbVie is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AbbVie stock

Net Profit Margin of AbbVie is 6.91 % in 2025.

Net Profit Margin of AbbVie changed from 7.59 % to 6.91 %, representing a -9.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin AbbVie since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's AbbVie with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AbbVie

All Key Metrics — AbbVie